《中国肺动脉高压诊断与治疗指南(2021版)》解读——动脉性肺动脉高压的危险分层

Interpretation of the Guidelines to the diagnosis and treatment of pulmonary hypertension in China(2021): risk stratification of pulmonary arterial hypertension

近10余年来动脉性肺动脉高压(PAH)的诊治取得了显著进步,患者生活质量改善和生存期延长很大程度上得益于规范危险分层、起始药物联合、长程序贯治疗和动态预后评估等不断优化的治疗策略。回顾过去30余年,研究人员综合患者临床症状、心功能、实验室检查指标等多项参数不断地更新和完善PAH危险分层量表,使其能够精准预测患者短期内的死亡风险,并根据不同的危险分层选择相应的治疗方案,同时在随访过程中动态更新危险分层信息,从而精准评估治疗效果,指导和调整治疗方案,改善患者的预后。文章将对PAH危险分层进行解读。

A significant progress in the diagnosis and treatment of pulmonary arterial hypertension(PAH) has been witnessed in the past decade. The survival and life quality improvement are benefited greatly from the optimize management strategy including standardized risk stratification,initial medication combination,long-term sequential treatment and dynamic prognosis evaluation. Researchers have successively updated and improved the risk stratification equation in the past 30 years based on multiple parameters including clinical manifestation,function,and lab tests,aming to accurately predict the patient’s short-term mortality risk,choose the corresponding treatment plan according to different risk stratifications,and dynamically update the risk stratification information during the follow-up process,so as to accurately evaluate the treatment effect,guide and adjust the treatment plan,and improve the prognosis of the patients. This article will interpret the risk stratification of PAH briefly.